Veritas In Silico

January 26, 2026

Company Name: Veritas In Silico Inc.
Representative: Shingo NAKAMURA,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact Person: Tsuneo GODA,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter

SpiroChem AG (Headquarters: Basel, Switzerland; CEO: Thomas Fessard, PhD; hereinafter referred to as "SpiroChem") and Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; CEO: Shingo Nakamura, PhD MBA, hereinafter referred to as "VIS") have entered into a Memorandum of Understanding (MoU) to conduct joint research for the discovery and experimental validation of mRNA-modulating chemical matter. SpiroChem and VIS jointly announce that the MoU has been executed.

The joint research initiative aims to create the world's most advanced and highest-level mRNA-targeted small molecule drugs by combining SpiroChem's world class macrocycle, peptide and peptoid chemistry capabilities. with VIS's AI-driven mRNA targeted drug discovery platform, aibVIS, and Cell Experiment Techniques. The research outcomes will be monetized through future joint licensing to third parties.

SpiroChem and VIS engaged in comprehensive discussions concerning the implementation specifics of this collaborative exploratory research initiative. After reaching a preliminary agreement in December 2025, the parties formally executed the MoU.

● Impact on Future Business Performance of VIS

The execution of MoU aligns with VIS' growth strategy and will contribute to its KPI, "4 New Contracts to be signed in FY2025" as announced in the "Company Presentation" dated February 13, 2025. This marks the third of 4 New Contracts to be signed in FY 2025. Furthermore, the small molecule drugs anticipated to emerge from this joint research are expected to contribute substantially to the creation of VIS's proprietary pipeline.

There will be no exchange of upfront payments or similar contractual considerations associated with the signing of the MOU. The research expenses for the joint research have already been incorporated into VIS's annual budget for the fiscal year ending December 2026, and consequently, no material impact on future business performance is currently anticipated.

In case any matters requiring disclosure arise in the future, they will be promptly disclosed.

For the announcement regarding the Collaboration by SpiroChem and VIS, please refer to the following page.

January 26, 2026

SpiroChem AG

Veritas In Silico Inc.

SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter

Basel, Switzerland and Tokyo, Japan - January 26, 2026

SpiroChem AG (“SpiroChem”) and Veritas In Silico Inc. (“VIS”) today announced the signing of a Memorandum of Understanding (MoU) to collaborate on the discovery and experimental validation of RNA modulating chemical matter. The collaboration brings together VIS’s advanced AI driven RNA design platform with SpiroChem’s world class macrocycle, peptide and peptoid chemistry capabilities.

Under the MoU, the parties intend to jointly explore novel macrocycles, peptides, peptoids and beyond Rule of 5 [*1] scaffolds that interact with RNA motifs of interest. The teams aim to generate high value experimental data, deepen understanding of structure–activity relationships for RNA recognition, and define design criteria that can inform future programs.

“ This collaboration pairs VIS’s leading RNA structure analytics and design with SpiroChem’s depth in macrocycles and peptide chemistry,” said Thomas Fessard, CEO and Co founder of SpiroChem. “Together we aim to expand the frontier of RNA binding chemical space and deliver high quality data that benefits partners across the RNA modulator field.”

“Combining our AI powered platform with SpiroChem’s libraries and medicinal chemistry expertise creates a powerful engine to evaluate and mature novel RNA binding scaffolds,” said Shingo Nakamura, CEO and Founder of Veritas In Silico. “We look forward to the scientific insights and collaboration opportunities this work can enable.”

Based on outcomes, the parties may explore future partnering, licensing or co development opportunities with biotech and pharmaceutical companies.

● Glossary for Reference

[*1] Rule of 5: An empirical rule that was proposed in 1997 by Dr. Lipinski and colleagues at Pfizer Inc. It is used primarily in the early stages of drug discovery as a screening criterion for compounds exhibiting "drug-like" properties, predicting low-molecular-weight compounds with high potential for oral administration.

Specifically, it requires that four criteria—molecular weight ≤500, lipophilicity (cLogP) ≤5, hydrogen bond donors (total OH and NH groups) ≤5, and hydrogen bond acceptors (total N and O atoms) ≤10—meet values ≤5 or ≤10, hence the name. Compounds that meet two or more of these four criteria are considered to possess "drug-like" properties.

For Further Information, Contact:

- SpiroChem AG Email for Inquiries: contact@spirochem.com
- Veritas In Silico Website Inquiry Form : https://www.veritasinsilico.com/en/contact/